Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection-the InC3 Study

Grants

Funding Acknowledgements

This work was supported by the National Institutes of Health (NIH; grants U19 AI088791 [to A. L. C.] and U19 AI066345 [to A. Y. K., T. M. A. and B. H. M.]); the National Institute on Drug Abuse, NIH (grants R01 DA031056 [to the InC<SUP>3</SUP> Study], R01 DA033541 [to A. Y. K.], R01 DA016017 [to K. P. and M. M.], and R01 DA15999-01 [to G. J. D., J. G., A. R. L., and M. H.]); the Victorian Operational Infrastructure Support Program (to the Burnet Institute); the National Health and Medical Research Council (postgraduate scholarship to R. S.-D., practitioner research fellowships to G. J. D. and A. R. L., senior research fellowships to M. H. and L. M., career development fellowship to J. G., and project grants 630483 [to the Hepatitis C Virus Incidence and Transmission Study-Community {HITS-c}] and 331312 [to the Networks 2 {N2} project]); Fonds de la Recherche du Quebec-Sante (research career awards to J. B. and N. H. S.); an Australian postgraduate PhD award (to B. H.); the Canadian Institutes of Health Research (grants MOP-103138 and MOP-106468 to J. B. and N. H. S.); the Netherlands National Institute for Public Health and the Environment (to the Amsterdam Cohort Study); the University of New South Wales Hepatitis C Vaccine Initiative (to the HITS-c); the Australian Centre for HIV and Hepatitis Virology Research (to the N2 project); and the Centre for Research Excellence into Injecting Drug Use (to M. H., G. J. D., L. M., J. G., and R. S. D.).